Mary Mullen

Medicine & Life Sciences

1. Ovarian Neoplasms 100%
2. Endometrial Neoplasms 61%
3. Neoplasms 55%
4. Organoids 42%
5. Platinum 38%
6. Frailty 33%
7. Gynecologic Surgical Procedures 30%
8. Drug Therapy 27%
9. Palliative Care 27%
10. Survival 27%
11. Homologous Recombination 27%
12. Hospices 26%
13. DNA Damage 26%
14. Medical Oncology 25%
15. Immunotherapy 25%
16. Placental Site Trophoblastic Tumor 23%
17. Biomarkers 22%
18. Hysterectomy 21%
19. Wounds and Injuries 21%
20. Uterine Neoplasms 20%
21. Vulvar Neoplasms 20%
22. Poly(ADP-ribose) Polymerase Inhibitors 19%
23. Cytoreduction Surgical Procedures 18%
24. Paclitaxel 17%
25. Terminal Care 16%
26. Ovarian Epithelial Carcinoma 16%
27. Subcutaneous Fat 16%
28. Intra-Abdominal Fat 16%
29. Tumor Burden 15%
30. Pandemics 15%
31. Glycolysis 15%
32. DNA Repair 14%
33. Immunohistochemistry 14%
34. Referral and Consultation 14%
35. Pelvis 14%
36. Bevacizumab 13%
37. Fluorescent Antibody Technique 13%
38. Anticoagulants 13%
39. Progestins 13%
40. Sutures 13%
41. Cell Line 13%
42. Carboplatin 13%
43. Therapeutics 12%
44. Confidence Intervals 11%
45. Primary Health Care 11%
46. Conjoined Twins 11%
47. Surgeons 10%
48. Receptor Protein-Tyrosine Kinases 9%
49. Venous Thromboembolism 9%
50. Sacrum 9%